Glial Cell Line-Derived Neurotrophic Factor - Therapeutic use
Research News and Information

Sunday, November 22, 2009

Cells therapy for Parkinson's disease--so close and so far away.

28 Jul 2009 One of the strategies of treating Parkinson's disease (PD) is the replacement of lost neurons in the substantia nigra with healthy dapamingergic cells. Potential sources for cells range from autologous grafts of dopamine secreting cells, fetal ... Read more...

Effects of delayed treatment with combined GDNF and continuous electrical stimulation on spiral ganglion cell survival in deafened guinea pigs.

29 Apr 2009 Electrical stimulation (ES) of spiral ganglion cells (SGC) via a cochlear implant is the standard treatment for profound sensor neural hearing loss. However, loss of hair cells as the morphological correlate of sensor neural hearing loss leads to ... Read more...

Effects of GDNF pretreatment on function and survival of transplanted fetal ventral mesencephalic cells in the 6-OHDA rat model of Parkinson's disease.

19 Apr 2009 Transplantation of fetal dopaminergic (DA) neurons offers an experimental therapy for Parkinson's disease (PD). The low availability and the poor survival and integration of transplanted cells in the host brain are major obstacles in this approach. ... Read more...

Latest indexed articles for 'Glial Cell Line-Derived Neurotrophic Factor - Therapeutic use'

These are the very latest articles for this heading:

• Cells therapy for Parkinson's disease--so close and so far away. 28 Jul 2009
• Effects of delayed treatment with combined GDNF and continuous electrical stimulation on spiral ganglion cell survival in deafened guinea pigs. 29 Apr 2009
• Effects of GDNF pretreatment on function and survival of transplanted fetal ventral mesencephalic cells in the 6-OHDA rat model of Parkinson's disease. 19 Apr 2009
• Excessive alcohol consumption is blocked by glial cell line-derived neurotrophic factor. 30 Jan 2009
• GDNF released from encapsulated cells suppresses seizure activity in the epileptic hippocampus. 5 Jan 2009
• Chapter 10: Conduit luminal additives for peripheral nerve repair. 30 Dec 2008
• Glial cell line-derived neurotrophic factor added to a sciatic nerve fragment grafted in a spinal cord gap ameliorates motor impairments in rats and increases local axonal growth. 30 Dec 2008
• Near complete rescue of experimental Parkinson's disease with intravenous, non-viral GDNF gene therapy. 21 Dec 2008
• A novel cell-based therapy for contusion spinal cord injury using GDNF-delivering NIH3T3 cells with dual reporter genes monitored by molecular imaging. 12 Aug 2008
• GDNF therapy for Parkinson's disease. 29 Jun 2008
• Emerging restorative treatments for Parkinson's disease. 12 May 2008
• Multiple molecular pathways are involved in the neuroprotection of GDNF against proteasome inhibitor induced dopamine neuron degeneration in vivo. 27 Apr 2008
• Neurotrophic factors as a therapeutic target for Parkinson's disease. 30 Mar 2008
• Exogenous administration of glial cell line-derived neurotrophic factor improves recovery after spinal cord injury. 23 Mar 2008
• Stimulation of axonal sprouting by trophic factors immobilized within the wound core. 8 Mar 2008
• A genetic fusion GDNF-C fragment of tetanus toxin prolongs survival in a symptomatic mouse ALS model. 30 Dec 2007
• Comparison of the therapeutic potential of adult and embryonic neural precursor cells in a rat model of Parkinson disease. 30 Dec 2007
• Emerging neuromodulatory molecules for the treatment of neurogenic erectile dysfunction caused by cavernous nerve injury. 30 Dec 2007
• Aspiration of a cervical spinal contusion injury in preparation for delayed peripheral nerve grafting does not impair forelimb behavior or axon regeneration. 13 Dec 2007
• [ALS and neurotrophic factors--HGF as a novel neurotrophic and neuroregenerative factor] 29 Sep 2007

See a longer list of these articles.

Technical information about 'Glial Cell Line-Derived Neurotrophic Factor'

Definition: The founding member of the glial cell line-derived neurotrophic factor family. It was originally characterized as a NERVE GROWTH FACTOR promoting the survival of MIDBRAIN dopaminergic NEURONS, and it has been studied as a potential treatment for PARKINSON DISEASE.

Registry Number: 0

Descriptor UI: D051100

Alternative terms: Glial Cell Line-Derived Neurotrophic Factor; Glial Cell Line Derived Neurotrophic Factor; GDNF Growth Factor; Growth Factor, GDNF; Glial Cell-Line Derived Neurotrophic Factor; GDNF;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; drug effects; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; ultrastructure; urine; chemistry; contraindications; agonists;

Tree Number: D12.644.276.860.381.500; D12.776.467.860.381.500; D12.776.641.600.381.500; D23.529.850.381.500;

History Note: 2006(1993)

Technical Notes: GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTORS is also available